Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany; Faculty of Health Sciences, NNF Center for Protein Research, University of Copenhagen, Copenhagen, Denmark; OmicEra Diagnostics GmbH, Planegg, Germany.
Department of Media, Cognition and Communication, University of Copenhagen, Copenhagen, Denmark; Uehiro Center for Practical Ethics, Oxford University, Oxford, UK.
Mol Cell Proteomics. 2021;20:100035. doi: 10.1074/mcp.RA120.002359. Epub 2021 Jan 11.
The goal of clinical proteomics is to identify, quantify, and characterize proteins in body fluids or tissue to assist diagnosis, prognosis, and treatment of patients. In this way, it is similar to more mature omics technologies, such as genomics, that are increasingly applied in biomedicine. We argue that, similar to those fields, proteomics also faces ethical issues related to the kinds of information that is inherently obtained through sample measurement, although their acquisition was not the primary purpose. Specifically, we demonstrate the potential to identify individuals both by their characteristic, individual-specific protein levels and by variant peptides reporting on coding single nucleotide polymorphisms. Furthermore, it is in the nature of blood plasma proteomics profiling that it broadly reports on the health status of an individual-beyond the disease under investigation. Finally, we show that private and potentially sensitive information, such as ethnicity and pregnancy status, can increasingly be derived from proteomics data. Although this is potentially valuable not only to the individual, but also for biomedical research, it raises ethical questions similar to the incidental findings obtained through other omics technologies. We here introduce the necessity of-and argue for the desirability for-ethical and human-rights-related issues to be discussed within the proteomics community. Those thoughts are more fully developed in our accompanying manuscript. Appreciation and discussion of ethical aspects of proteomic research will allow for deeper, better-informed, more diverse, and, most importantly, wiser guidelines for clinical proteomics.
临床蛋白质组学的目标是鉴定、定量和描述体液或组织中的蛋白质,以辅助患者的诊断、预后和治疗。在这方面,它与更成熟的组学技术(如基因组学)相似,这些技术越来越多地应用于生物医学领域。我们认为,与这些领域一样,蛋白质组学也面临着与通过样本测量获得的信息类型相关的伦理问题,尽管这些信息的获取不是主要目的。具体来说,我们证明了通过个体特有的、个体特异性的蛋白质水平以及报告编码单核苷酸多态性的变异肽来识别个体的潜力。此外,血浆蛋白质组学分析的性质是广泛报告个体的健康状况——超出了正在研究的疾病。最后,我们表明,私人的、潜在敏感的信息,如种族和妊娠状况,可以越来越多地从蛋白质组学数据中得出。尽管这不仅对个人,而且对生物医学研究都具有潜在的价值,但它也引发了与通过其他组学技术获得的偶然发现类似的伦理问题。我们在这里引入了在蛋白质组学领域内讨论伦理和人权相关问题的必要性,并主张这样做的可取性。这些想法在我们的相关论文中有更全面的阐述。对蛋白质组学研究伦理方面的理解和讨论将为临床蛋白质组学制定出更深入、更明智、更具信息性、更多样化、最重要的是更明智的指导方针。